Recently, medical research using big data has become very popular, and its value has become increasingly recognized. The Korean National Health Information Database (NHID) is representative of big data that combines information obtained from the National Health Insurance Service collected for claims and reimbursement of health care services and results obtained from general health examinations provided to all Korean adults. This database has several strengths and limitations. Given the large size, various laboratory data, and questionnaires obtained from medical check-ups, their longitudinal nature, and long-term accumulation of data since 2002, carefully designed studies may provide valuable information that is difficult to obtain from other forms of research. However, consideration of possible bias and careful interpretation when defining causal relationships is also important because the data were not collected for research purposes. After the NHID became publicly available, research and publications based on this database have increased explosively, especially in the field of diabetes and metabolism. This article reviews the history, structure, and characteristics of the Korean NHID. Recent trends in big data research using this database, commonly used operational diagnosis, and representative studies have been introduced. We expect further progress and expansion of big data research using the Korean NHID.
Citations
Citations to this article as recorded by
Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data Jinyoung Kim, Bongseong Kim, Mee Kyoung Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon Diabetes, Obesity and Metabolism.2024; 26(2): 567. CrossRef
Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults Jin Hwa Kim, Young Sang Lyu, Mee Kyoung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon Diabetes, Obesity and Metabolism.2024; 26(1): 180. CrossRef
Diabetes severity and the risk of depression: A nationwide population-based study Yunjung Cho, Bongsung Kim, Hyuk-Sang Kwon, Kyungdo Han, Mee Kyoung Kim Journal of Affective Disorders.2024; 351: 694. CrossRef
Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee Endocrinology and Metabolism.2023; 38(5): 525. CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Predicting the Risk of Insulin-Requiring Gestational Diabetes before Pregnancy: A Model Generated from a Nationwide Population-Based Cohort Study in Korea Seung-Hwan Lee, Jin Yu, Kyungdo Han, Seung Woo Lee, Sang Youn You, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim Endocrinology and Metabolism.2023; 38(1): 129. CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko Diabetes & Metabolism Journal.2023; 47(2): 201. CrossRef
Comorbidity Differences by Trajectory Groups as a Reference for Identifying Patients at Risk for Late Mortality in Childhood Cancer Survivors: Longitudinal National Cohort Study Hyery Kim, Hae Reong Kim, Sung Han Kang, Kyung-Nam Koh, Ho Joon Im, Yu Rang Park JMIR Public Health and Surveillance.2023; 9: e41203. CrossRef
Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim Respiratory Research.2023;[Epub] CrossRef
Investigation of the Relationship Between Psychiatry Visit and Suicide After Deliberate Self-harm: Longitudinal National Cohort Study Hye Hyeon Kim, Chanyoung Ko, Ji Ae Park, In Han Song, Yu Rang Park JMIR Public Health and Surveillance.2023; 9: e41261. CrossRef
Reply Yeonghee Eun, Hyungjin Kim, Jaejoon Lee Arthritis & Rheumatology.2023; 75(6): 1081. CrossRef
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017 Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(3): 347. CrossRef
Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia Bo-Guen Kim, Danbee Kang, Kyung Hoon Min, Juhee Cho, Kyeongman Jeon Antibiotics.2023; 12(6): 984. CrossRef
Cumulative exposure to metabolic syndrome increases thyroid cancer risk in young adults: a population-based cohort study Jinyoung Kim, Kyungdo Han, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon The Korean Journal of Internal Medicine.2023; 38(4): 526. CrossRef
Risk of developing chronic kidney disease in young-onset Type 2 diabetes in Korea Joonyub Lee, Seung-Hwan Lee, Kun-Ho Yoon, Jae Hyoung Cho, Kyungdo Han, Yeoree Yang Scientific Reports.2023;[Epub] CrossRef
Factors Affecting High Body Weight Variability Kyungdo Han, Mee Kyoung Kim Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163. CrossRef
Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek Frontiers in Endocrinology.2023;[Epub] CrossRef
The impact of diabetes status on total and site-specific cancer risk in the elderly population: A nationwide cohort study Kyuho Kim, Bongseong Kim, Hyunho Kim, Hyung Soon Park, Yu-Bae Ahn, Seung-Hyun Ko, Kyungdo Han, Jae-Seung Yun Diabetes Research and Clinical Practice.2023; 203: 110866. CrossRef
Response to comments of Lai et al. “Proposal of one option for patient-centered, heterogeneous selection of antidiabetic drug” Sunyoung Kim, Sang Youl Rhee Diabetes Research and Clinical Practice.2023; 203: 110864. CrossRef
Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis Mee Kyoung Kim, Kyungdo Han, Hyuk-Sang Kwon, Soon Jib Yoo Endocrinology and Metabolism.2023; 38(4): 426. CrossRef
Increased risk of ischemic stroke associated with elevated gamma-glutamyl transferase level in adult cancer survivors: a population-based cohort study Kyuwoong Kim, Hyeyun Jung, Edvige Di Giovanna, Tae Joon Jun, Young-Hak Kim Scientific Reports.2023;[Epub] CrossRef
Real-world data analysis on effectiveness of integrative therapies: A practical guide to study design and data analysis using healthcare databases Ye-Seul Lee, Yoon Jae Lee, In-Hyuk Ha Integrative Medicine Research.2023; 12(4): 101000. CrossRef
Possible Applications of the Korean Experience in the Development of Croatian Healthcare System Predrag Bejakovic, Romina P Družeta, Ohmin Kwon Science, Art and Religion.2023; 2(1--2): 26. CrossRef
Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee Scientific Reports.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Long-Term Cumulative Exposure to High γ-Glutamyl Transferase Levels and the Risk of Cardiovascular Disease: A Nationwide Population-Based Cohort Study Han-Sang Baek, Bongseong Kim, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Sang-Ah Chang, Kyungdo Han, Jae-Seung Yun Endocrinology and Metabolism.2023; 38(6): 770. CrossRef
Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki-Hyun Baek, Ki-Ho Song, Mee Kyoung Kim, Hyuk-Sang Kwon Diabetes Research and Clinical Practice.2022; 194: 110187. CrossRef
Chronic viral hepatitis accelerates lung function decline in smokers Suh-Young Lee, Sun-Sin Kim, So-Hee Lee, Heung-Woo Park Clinical and Experimental Medicine.2022; 23(6): 2159. CrossRef
Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that ultimately develops into end-stage kidney disease (ESKD) when not managed appropriately. Substantial risk of ESKD remains even with intensive management of hyperglycemia and risk factors of DKD and timely use of renin-angiotensin-aldosterone inhibitors. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce hyperglycemia primarily by inhibiting glucose and sodium reabsorption in the renal proximal tubule. Currently, their effects expand to prevent or delay cardiovascular and renal adverse events, even in those without diabetes. In dedicated renal outcome trials, SGLT2 inhibitors significantly reduced the risk of composite renal adverse events, including the development of ESKD or renal replacement therapy, which led to the positioning of SGLT2 inhibitors as the mainstay of chronic kidney disease management. Multiple mechanisms of action of SGLT2 inhibitors, including hemodynamic, metabolic, and anti-inflammatory effects, have been proposed. Restoration of tubuloglomerular feedback is a plausible explanation for the alteration in renal hemodynamics induced by SGLT2 inhibition and for the associated renal benefit. This review discusses the clinical rationale and mechanism related to the protection SGLT2 inhibitors exert on the kidney, focusing on renal hemodynamic effects.
Citations
Citations to this article as recorded by
Using intravoxel incoherent motion imaging to evaluate uric acid-induced renal injury and efficacy after treatment Zhong-Yuan Cheng, Shang-Ao Gong, Ping-Kang Chen, Zong-Chao Yu, Chen Qiu, Ji-Xin Lin, Jia-Bin Mo, Long Qian, You-Zhen Feng, Xiang-Ran Cai British Journal of Radiology.2024; 97(1153): 274. CrossRef
Rethinking eGFR Comparisons in SGLT2 Inhibitor Research Yuzuru Ohshiro Journal of the American College of Cardiology.2024; 83(9): e87. CrossRef
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis Yunke Ma, Chu Lin, Xiaoling Cai, Suiyuan Hu, Xingyun Zhu, Fang Lv, Wenjia Yang, Linong Ji Acta Diabetologica.2023; 60(3): 435. CrossRef
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials Mengnan Li, Jian Zhang, Guimei Yang, Jiaxin Zhang, Minmin Han, Yi Zhang, Yunfeng Liu European Journal of Clinical Pharmacology.2023; 79(6): 859. CrossRef
Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018 Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes Sjoukje van der Hoek, Jeroen V. Koomen, Erik J. M. van Bommel, Charlotte M. Mosterd, Rosalie A. Scholtes, Anne C. Hesp, Jasper Stevens, Daniel H. van Raalte, Hiddo J. L. Heerspink Journal of Personalized Medicine.2023; 13(5): 747. CrossRef
Osteopontin as a Biomarker in Chronic Kidney Disease Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas Biomedicines.2023; 11(5): 1356. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee Metabolism.2023; 145: 155612. CrossRef
Synthesis and biological profile of benzoxazolone derivatives Parteek Prasher, Tanisqa Mall, Mousmee Sharma Archiv der Pharmazie.2023;[Epub] CrossRef
SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression Ye Jin Kim, Jonghwa Jin, Dong-Ho Kim, Daehoon Kim, You Mie Lee, Jun-Kyu Byun, Yeon-Kyung Choi, Keun-Gyu Park Inflammation Research.2023; 72(10-11): 1981. CrossRef
Pancreatic beta cell homeostasis is crucial for the synthesis and secretion of insulin; disruption of homeostasis causes diabetes, and is a treatment target. Adaptation to endoplasmic reticulum (ER) stress through the unfolded protein response (UPR) and adequate regulation of autophagy, which are closely linked, play essential roles in this homeostasis. In diabetes, the UPR and autophagy are dysregulated, which leads to beta cell failure and death. Various studies have explored methods to preserve pancreatic beta cell function and mass by relieving ER stress and regulating autophagic activity. To promote clinical translation of these research results to potential therapeutics for diabetes, we summarize the current knowledge on ER stress and autophagy in human insulin-secreting cells.
Citations
Citations to this article as recorded by
Glucolipotoxicity Suppressed Autophagy and Insulin Contents in Human Islets, and Attenuation of PERK Activity Enhanced Them in an ATG7-Dependent Manner Seoil Moon, Ji Yoon Lim, Mirang Lee, Youngmin Han, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Mi Na Kim, Kyong Soo Park, Hye Seung Jung Diabetes & Metabolism Journal.2024; 48(2): 231. CrossRef
Endoplasmic reticulum stress: A possible connection between intestinal inflammation and neurodegenerative disorders Giorgio Vivacqua, Romina Mancinelli, Stefano Leone, Rosa Vaccaro, Ludovica Garro, Simone Carotti, Ludovica Ceci, Paolo Onori, Luigi Pannarale, Antonio Franchitto, Eugenio Gaudio, Arianna Casini Neurogastroenterology & Motility.2024;[Epub] CrossRef
Pancreatic islet remodeling in cotadutide-treated obese mice Renata Spezani, Thatiany Souza Marinho, Luiz E. Macedo Cardoso, Marcia Barbosa Aguila, Carlos Alberto Mandarim-de-Lacerda Life Sciences.2023; 327: 121858. CrossRef
Modulation of Unfolded Protein Response Restores Survival and Function of β-Cells Exposed to the Endocrine Disruptor Bisphenol A Laura Maria Daian, Gabriela Tanko, Andrei Mircea Vacaru, Luiza Ghila, Simona Chera, Ana-Maria Vacaru International Journal of Molecular Sciences.2023; 24(3): 2023. CrossRef
Interplay of skeletal muscle and adipose tissue: sarcopenic obesity Min Jeong Park, Kyung Mook Choi Metabolism.2023; 144: 155577. CrossRef
Identification and analysis of type 2 diabetes-mellitus-associated autophagy-related genes Kun Cui, Zhizheng Li Frontiers in Endocrinology.2023;[Epub] CrossRef
Sestrin2 in diabetes and diabetic complications Xiaodan Zhang, Zirui Luo, Jiahong Li, Yaxuan Lin, Yu Li, Wangen Li Frontiers in Endocrinology.2023;[Epub] CrossRef
Crosstalk between autophagy and insulin resistance: evidence from different tissues Asie Sadeghi, Maryam Niknam, Mohammad Amin Momeni-Moghaddam, Maryam Shabani, Hamid Aria, Alireza Bastin, Maryam Teimouri, Reza Meshkani, Hamed Akbari European Journal of Medical Research.2023;[Epub] CrossRef
Beta cell lipotoxicity in the development of type 2 diabetes: the need for species-specific understanding Patricia Thomas, Meurig T. Gallagher, Gabriela Da Silva Xavier Frontiers in Endocrinology.2023;[Epub] CrossRef
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.
Citations
Citations to this article as recorded by
The role of adherence in patients with chronic diseases Michel Burnier European Journal of Internal Medicine.2024; 119: 1. CrossRef
Bempedoic acid: new evidence and recommendations on use Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach Current Opinion in Lipidology.2024; 35(1): 41. CrossRef
Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu Frontiers in Endocrinology.2024;[Epub] CrossRef
Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy Monika I. Konaklieva, Balbina J. Plotkin Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect? Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis Journal of Cardiovascular Development and Disease.2024; 11(3): 72. CrossRef
Liver cancer cells as the model for developing liver-targeted RNAi therapeutics Beibei Hou, Linhui Qin, Linfeng Huang Biochemical and Biophysical Research Communications.2023; 644: 85. CrossRef
Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization C. M. Schooling, J. V. Zhao Current Cardiology Reports.2023; 25(2): 67. CrossRef
Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi Food Science & Nutrition.2023; 11(6): 2620. CrossRef
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206. CrossRef
Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos Journal of the American Heart Association.2023;[Epub] CrossRef
The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng Frontiers in Physiology.2023;[Epub] CrossRef
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux Alejandro Gugliucci Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef
Remnant cholesterol, vascular risk, and prevention of atherosclerosis Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206. CrossRef
Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis Pharmacy.2023; 11(4): 130. CrossRef
Advances in Treatment of Dyslipidemia Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk International Journal of Molecular Sciences.2023; 24(17): 13288. CrossRef
Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos Biomedicines.2023; 11(10): 2696. CrossRef
Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li Scientific Reports.2023;[Epub] CrossRef
Dysregulation of Cholesterol Homeostasis in Ovarian Cancer Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung Current Oncology.2023; 30(9): 8386. CrossRef
Riesgo residual. Conclusiones Ángel Cequier, José Luis Zamorano Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef
Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen Frontiers in Endocrinology.2023;[Epub] CrossRef
Bibliometric analysis of residual cardiovascular risk: trends and frontiers Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li Journal of Health, Population and Nutrition.2023;[Epub] CrossRef
Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran Biology.2022; 11(9): 1308. CrossRef
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia Joon Ho Moon, Kyuho Kim, Sung Hee Choi Endocrinology and Metabolism.2022; 37(4): 575. CrossRef
Receiver Operator Characteristic (ROC) Analysis of Lipids, Proteins, DNA Oxidative Damage, and Antioxidant Defense in Plasma and Erythrocytes of Young Reproductive-Age Men with Early Stages of Type 1 Diabetes Mellitus (T1DM) Nephropathy in the Irkutsk Reg Marina Darenskaya, Elena Chugunova, Sergey Kolesnikov, Natalya Semenova, Isay Michalevich, Olga Nikitina, Anastasya Lesnaya, Lyubov Kolesnikova Metabolites.2022; 12(12): 1282. CrossRef
Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng Critical Reviews in Food Science and Nutrition.2022; : 1. CrossRef
Endothelial dysfunction is strongly linked with inflammatory responses, which can impact cardiovascular disease. Recently, G protein-coupled receptor 40 (GPR40) has been investigated as a modulator of metabolic stress; however, the function of GPR40 in vascular endothelial cells has not been reported. We analyzed whether treatment of GPR40-specific agonists modulated the inflammatory responses in human umbilical vein endothelial cells (HUVECs). Treatment with LY2922470, a GPR40 agonist, significantly reduced lipopolysaccharide (LPS)-mediated nuclear factor-kappa B (NF-κB) phosphorylation and movement into the nucleus from the cytosol. However, treatment with another GPR40 agonist, TAK875, did not inhibit LPS-induced NF-κB activation. LPS treatment induced expression of adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) and attachment of THP-1 cells to HUVECs, which were all decreased by LY2922470 but not TAK875. Our results showed that ligand-dependent agonism of GPR40 is a promising therapeutic target for overcoming inflammatory reactions in the endothelium.
Citations
Citations to this article as recorded by
Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships Abhik Paul, Sourin Nahar, Pankaj Nahata, Arnab Sarkar, Avik Maji, Ajeya Samanta, Sanmoy Karmakar, Tapan Kumar Maity European Journal of Medicinal Chemistry.2024; 264: 115990. CrossRef
GPR40 deficiency worsens metabolic syndrome‐associated periodontitis in mice Yanchun Li, Zhongyang Lu, Cameron L. Kirkwood, Keith L. Kirkwood, Stephen A. Wank, Ai‐Jun Li, Maria F. Lopes‐Virella, Yan Huang Journal of Periodontal Research.2023; 58(3): 575. CrossRef
Signaling pathways and intervention for therapy of type 2 diabetes mellitus Rong Cao, Huimin Tian, Yu Zhang, Geng Liu, Haixia Xu, Guocheng Rao, Yan Tian, Xianghui Fu MedComm.2023;[Epub] CrossRef
G Protein-Coupled Receptor 40 Agonist LY2922470 Alleviates Ischemic-Stroke-Induced Acute Brain Injury and Functional Alterations in Mice Yingyu Lu, Wanlu Zhou, Qinghua Cui, Chunmei Cui International Journal of Molecular Sciences.2023; 24(15): 12244. CrossRef
AM1638, a GPR40-Full Agonist, Inhibited Palmitate- Induced ROS Production and Endoplasmic Reticulum Stress, Enhancing HUVEC Viability in an NRF2-Dependent Manner Hwan-Jin Hwang, Joo Won Kim, SukHwan Yun, Min Jeong Park, Eyun Song, Sooyeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo Endocrinology and Metabolism.2023; 38(6): 760. CrossRef
Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders Hong-Ping Guan, Yusheng Xiong Frontiers in Pharmacology.2022;[Epub] CrossRef
This study aimed to determine the influence of pre-pregnancy body mass index on pregnancy outcomes in gestational diabetes mellitus (GDM), comparing underweight patients with GDM with normal weight patients with GDM. Maternal baseline characteristics, ultrasonographic results, and pregnancy and neonatal outcomes were reviewed in 946 women with GDM with singleton pregnancies. Underweight patients with GDM showed a benign course in most aspects during pregnancy, except for developing a higher risk of giving birth to small for gestational age neonates. Underweight women with GDM required less insulin treatment, had a higher rate of vaginal delivery, and had a lower rate of cesarean delivery. In addition, their neonates were more likely to have fetal abdominal circumference and estimated fetal weight below the 10th percentile both at the time of GDM diagnosis and before delivery. Notably, their risk for preeclampsia and macrosomia were lower. Collectively, our data suggest that underweight women with GDM may require a different approach in terms of diagnosis and management throughout their pregnancy.
Citations
Citations to this article as recorded by
Challenges in the management of gestational diabetes mellitus in anorexia nervosa Rija Siddiqui, Carrie J McAdams Psychiatry Research Case Reports.2024; 3(1): 100215. CrossRef
Obesity Is Associated With Higher Risk of Adverse Maternal and Neonatal Outcomes Than Supervised Gestational Diabetes Namju Seo, You Min Lee, Ye-jin Kim, Ji-hee Sung, Kyu-Yeon Hur, Suk-Joo Choi, Cheong-Rae Roh, Soo-young Oh Journal of Korean Medical Science.2023;[Epub] CrossRef
Maternal pre-pregnancy obesity modifies the association between first-trimester thyroid hormone sensitivity and gestational Diabetes Mellitus: a retrospective study from Northern China Honglin Sun, Yibo Zhou, Jia Liu, Ying Wang, Guang Wang Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Background This study aimed to determine the optimal cut-off values of visceral fat area (VFA) and visceral-to-subcutaneous fat ratio (VSR) for predicting incident type 2 diabetes mellitus (T2DM).
Methods A total of 10,882 individuals (6,835 men; 4,047 women) free of T2DM at baseline aged between 30 and 79 years who underwent abdominal computed tomography scan between 2012 and 2013 as a part of routine health check-ups were included and followed. VFA, subcutaneous fat area, and VSR on L3 vertebral level were measured at baseline.
Results During a median follow-up of 4.8 years, 730 (8.1% for men; 4.3% for women) incident cases of T2DM were identified. Receiver operating characteristic curve analysis showed that the optimal cut-off values of VFA and VSR for predicting incident T2DM were 130.03 cm2 and 1.08 in men, respectively, and 85.7 cm2 and 0.48 in women, respectively. Regardless of sex, higher VFA and VSR were significantly associated with a higher risk of incident T2DM. Compared with the lowest quartiles of VFA and VSR, the highest quartiles had adjusted odds ratios of 2.62 (95% confidence interval [CI], 1.73 to 3.97) and 1.55 (95% CI, 1.14 to 2.11) in men, respectively, and 32.49 (95% CI, 7.42 to 142.02) and 11.07 (95% CI, 3.89 to 31.50) in women, respectively.
Conclusion Higher VFA and VSR at baseline were independent risk factors for the development of T2DM. Sex-specific reference values for visceral fat obesity (VFA ≥130 cm2 or VSR ≥1.0 in men; VFA ≥85 cm2 or VSR ≥0.5 in women) are proposed for the prediction of incident T2DM.
Citations
Citations to this article as recorded by
Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study Mohammad Jalali, Zahra Bahadoran, Parvin Mirmiran, Fereidoun Azizi, Farhad Hosseinpanah BMC Public Health.2024;[Epub] CrossRef
Should insulin resistance (HOMA-IR), insulin secretion (HOMA-β), and visceral fat area be considered for improving the performance of diabetes risk prediction models Huan Hu, Tohru Nakagawa, Toru Honda, Shuichiro Yamamoto, Tetsuya Mizoue BMJ Open Diabetes Research & Care.2024; 12(1): e003680. CrossRef
Adipose organ dysfunction and type 2 diabetes: Role of nitric oxide Zahra Bahadoran, Parvin Mirmiran, Asghar Ghasemi Biochemical Pharmacology.2024; 221: 116043. CrossRef
Prediction of high visceral adipose tissue for sex‐specific community residents in Taiwan Yu‐Hsuan Chang, Chin‐Sung Chang, Chieh‐Yu Liu, Yin‐Fan Chang, Shiow‐Ching Shun Nursing & Health Sciences.2024;[Epub] CrossRef
Body Composition and Metabolic Dysfunction Really Matter for the Achievement of Better Outcomes in High-Grade Serous Ovarian Cancer Mauricio A. Cuello, Fernán Gómez, Ignacio Wichmann, Felipe Suárez, Sumie Kato, Elisa Orlandini, Jorge Brañes, Carolina Ibañez Cancers.2023; 15(4): 1156. CrossRef
MEDICINAL BIOMAGNETISM FOR THE TREATMENT OF OBESITY Ana Vergínia Campagnollo Bueno, Michelli Gonçalves Seneda, Ângela Mara Rambo, Ana Clara Campagnolo Gonçalves Toledo, Caroline Cabral de Azevedo, Adriane Viapiana Bossa Health and Society.2023; 3(01): 411. CrossRef
Cumulative exposure to metabolic syndrome in a national population-based cohort of young adults and sex-specific risk for type 2 diabetes Min-Kyung Lee, Jae-Hyuk Lee, Seo Young Sohn, Jiyeon Ahn, Oak-Kee Hong, Mee-Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han, Hyuk-Sang Kwon Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
The correlation between visceral fat/subcutaneous fat area ratio and monocyte/high-density lipoprotein ratio in patients with type 2 diabetes mellitus and albuminuria Haiyan Lin, Jun Zhu, Chen Zheng, Xiaoming Xu, Shandong Ye Journal of Diabetes and its Complications.2023; 37(11): 108521. CrossRef
Effects of the abdominal fat distribution on the relationship between exposure to air pollutants and thyroid hormones among Korean adult males Hyun-Jin Kim, Byungmi Kim, Seyoung Kim, Hyuktae Kwon, Jae Moon Yun, Belong Cho, Jin-Ho Park European Journal of Medical Research.2023;[Epub] CrossRef
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe Clinical and Molecular Hepatology.2023; 29(4): 987. CrossRef
Visceral adipose tissue reference data computed for GE HealthCare DXA from the National Health and Nutrition Examination Survey data set Jonathan P. Bennett, Brandon K. Quon, Bo Fan, En Liu, Leila Kazemi, Rosa C. Villegas‐Valle, Raj Ahgun, Xian‐pin Wu, Hou‐De Zhou, Ying Lu, John A. Shepherd Obesity.2023; 31(12): 2947. CrossRef
Comparison of bioelectrical body and visceral fat indices and anthropometric measures in relation to type 2 diabetes by sex among Chinese adults, a cross-sectional study Jiangshan He, Binbin Zhang, Yaqi Fan, Yuxue Wang, Mianzhi Zhang, Chunjun Li, Li Zhang, Pei Guo, Minying Zhang Frontiers in Public Health.2023;[Epub] CrossRef
The predictive significance of lipid accumulation products for future diabetes in a non-diabetic population from a gender perspective: an analysis using time-dependent receiver operating characteristics Jiajun Qiu, Maobin Kuang, Yang Zou, Ruijuan Yang, Qing Shangguan, Dingyang Liu, Guotai Sheng, Wei Wang Frontiers in Endocrinology.2023;[Epub] CrossRef
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy Ren Jie Phang, Rebecca H. Ritchie, Derek J. Hausenloy, Jarmon G. Lees, Shiang Y. Lim Cardiovascular Research.2022;[Epub] CrossRef
Implication of Sex Differences in Visceral Fat for the Assessment of Incidence Risk of Type 2 Diabetes Mellitus Sang Hyeon Ju, Hyon-Seung Yi Diabetes & Metabolism Journal.2022; 46(3): 414. CrossRef
Visceral fat area and body fat percentage measured by bioelectrical impedance analysis correlate with glycometabolism Shuying Li, Shaoping Li, Jie Ding, Weihong Zhou BMC Endocrine Disorders.2022;[Epub] CrossRef
The Demographic Specific Abdominal Fat Composition and Distribution Trends in US Adults from 2011 to 2018 Furong Xu, Jacob E. Earp, Bryan J. Blissmer, Ingrid E. Lofgren, Matthew J. Delmonico, Geoffrey W. Greene International Journal of Environmental Research and Public Health.2022; 19(19): 12103. CrossRef
Visceral Obesity Is a More Important Factor for Colorectal Adenomas than Skeletal Muscle or Body Fat Ji Yeon Seo, Yoo Min Han, Su Jin Chung, Seon Hee Lim, Jung Ho Bae, Goh Eun Chung Cancers.2022; 14(21): 5256. CrossRef
Recent Advances in Visceral Obesity and Related Diseases 佳佳 魏 Advances in Clinical Medicine.2022; 12(12): 11686. CrossRef
Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China Pingping Yu, Huachao Yang, Xiaoya Qi, Ruixue Bai, Shouqin Zhang, Jianping Gong, Ying Mei, Peng Hu Lipids in Health and Disease.2022;[Epub] CrossRef
Background Creatinine-to-cystatin C ratio is recently suggested to be a surrogate marker for sarcopenia. However, little is known about its association with diabetes. This study aimed to fill in this gap based on a large-scale prospective cohort.
Methods A population-based representative sample of 5,055 participants aged ≥45 years from the China Health and Retirement Longitudinal Study was enrolled between 2011 and 2012 and followed at least once during the subsequent surveys at 2013, 2015, or 2018. Creatinine-to-cystatin C ratio was calculated and normalized by body weight. Incident diabetes was ascertained by plasma glucose, glycosylated hemoglobin, self-reported history, or use of anti-diabetic drugs. Logistic regression analysis and mediation analysis were employed.
Results During follow-up, 634 participants developed diabetes. The risk of diabetes was gradually and significantly decreased with increased normalized creatinine–cystatin C ratio. The multivariable-adjusted odds ratio for diabetes was 0.91 (95% confidence interval, 0.83 to 0.99) per 1 standard deviation higher of normalized creatinine-to-cystatin C ratio, and this relationship remained significant after controlling for muscle strength. The risk reduction in diabetes was significantly larger in participants with normal-weight and high normalized creatinine-to-cystatin C ratio compared with those with overweight/obesity and high normalized creatinine-to-cystatin C ratio (Pinteraction=0.01). Insulin resistance and inflammation appeared to be key mediators accounting for the observed relationship between normalized creatinine-to-cystatin C ratio and risk of diabetes, with their mediating effect being 93.1% and 22.0%, respectively.
Conclusion High normalized creatinine-to-cystatin C ratio is associated with reduced risk of diabetes in middle-aged and older adults.
Citations
Citations to this article as recorded by
Muscle Quality in Relation to Prediabetes Phenotypes: A Population-Based Study With Mediation Analysis Shanhu Qiu, Xue Cai, Xiaoying Zhou, Jinshui Xu, Zilin Sun, Haijian Guo, Tongzhi Wu The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1151. CrossRef
Sex‐specific associations between skeletal muscle mass and incident diabetes: A population‐based cohort study Dan Liu, Nan Li, Yiling Zhou, Miye Wang, Peige Song, Changzheng Yuan, Qingyang Shi, Hui Chen, Kaixin Zhou, Huan Wang, Tao Li, Xiong‐Fei Pan, Haoming Tian, Sheyu Li Diabetes, Obesity and Metabolism.2024; 26(3): 820. CrossRef
Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers Justyna Rentflejsz, Zyta Beata Wojszel Journal of Clinical Medicine.2024; 13(4): 1107. CrossRef
Associations of muscle mass and strength with new-onset diabetes among middle-aged and older adults: evidence from the China health and retirement longitudinal study (CHARLS) Yun-Yun He, Mei-Ling Jin, Xiang-Yang Fang, Xiao-Juan Wang Acta Diabetologica.2024;[Epub] CrossRef
The serum creatinine to cystatin C to waist circumference ratios predicts risk for type 2 diabetes: A Chinese cohort study Yinfei Chen, Weiheng Wen, Zhiliang Mai, Ming Wang, Hong Chen, Jia Sun Journal of Diabetes.2023; 15(10): 808. CrossRef
Associations of sarcopenia with peak expiratory flow among community-dwelling elderly population: based on the China Health and Retirement Longitudinal Study (CHARLS) Yun-Yun He, Mei-Ling Jin, Jing Chang, Xiao-Juan Wang European Geriatric Medicine.2023; 15(1): 95. CrossRef
Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study Eyun Song, Soon Young Hwang, Min Jeong Park, Ahreum Jang, Kyeong Jin Kim, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi Metabolism.2023; 148: 155678. CrossRef
Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sungrae Kim
Diabetes Metab J. 2022;46(3):464-475. Published online March 3, 2022
Background We evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS), and American Diabetes Association (ADA) guidelines.
Methods This retrospective cohort study collected electronic medical record data from patients with T2DM (≥20 years) managed by endocrinologists from 15 hospitals in Korea (January to December 2019). Patients were categorized according to guidelines to assess LDL-C target achievement. KDA (2019): Very High-I (atherosclerotic cardiovascular disease [ASCVD]) <70 mg/dL; Very High-II (target organ damage [TOD], or cardiovascular risk factors [CVRFs]) <70 mg/dL; high (others) <100 mg/dL. ESC/EAS (2019): Very High-I (ASCVD): <55 mg/dL; Very High-II (TOD or ≥3-CVRF) <55 mg/dL; high (diabetes ≥10 years without TOD plus any CVRF) <70 mg/dL; moderate (diabetes <10 years without CVRF) <100 mg/dL. ADA (2019): Very High-I (ASCVD); Very High-II (age ≥40+ TOD, or any CVRF), for high intensity statin or statin combined with ezetimibe.
Results Among 2,000 T2DM patients (mean age 62.6 years; male 55.9%; mean glycosylated hemoglobin 7.2%) ASCVD prevalence was 24.7%. Of 1,455 (72.8%) patients treated with statins, 73.9% received monotherapy. According to KDA guidelines, LDL-C target achievement rates were 55.2% in Very High-I and 34.9% in Very High-II patients. With ESC/EAS guidelines, target attainment rates were 26.6% in Very High-I, 15.7% in Very High-II, and 25.9% in high risk patients. Based on ADA guidelines, most patients (78.9%) were very-high risk; however, only 15.5% received high-intensity statin or combination therapy.
Conclusion According to current dyslipidemia management guidelines, LDL-C goal achievement remains suboptimal in Korean patients with T2DM.
Citations
Citations to this article as recorded by
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki PLOS ONE.2024; 19(2): e0299035. CrossRef
Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku Frontiers in Endocrinology.2024;[Epub] CrossRef
Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon Journal of Lipid and Atherosclerosis.2023; 12(1): 12. CrossRef
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon Diabetes & Metabolism Journal.2023; 47(1): 1. CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus Kyung Ae Lee The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu Diabetes Research and Clinical Practice.2022; 191: 110067. CrossRef
Background The onset and progression of type 1 diabetes mellitus (T1DM) is closely related to autoimmunity. Effective monitoring of the immune system and developing targeted therapies are frontier fields in T1DM treatment. Currently, the most available tissue that reflects the immune system is peripheral blood mononuclear cells (PBMCs). Thus, the aim of this study was to identify key PBMC biomarkers of T1DM.
Methods Common differentially expressed genes (DEGs) were screened from the Gene Expression Omnibus (GEO) datasets GSE9006, GSE72377, and GSE55098, and PBMC mRNA expression in T1DM patients was compared with that in healthy participants by GEO2R. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) network analyses of DEGs were performed using the Cytoscape, DAVID, and STRING databases. The vital hub genes were validated by reverse transcription-polymerase chain reaction using clinical samples. The disease-gene-drug interaction network was built using the Comparative Toxicogenomics Database (CTD) and Drug Gene Interaction Database (DGIdb).
Results We found that various biological functions or pathways related to the immune system and glucose metabolism changed in PBMCs from T1DM patients. In the PPI network, the DEGs of module 1 were significantly enriched in processes including inflammatory and immune responses and in pathways of proteoglycans in cancer. Moreover, we focused on four vital hub genes, namely, chitinase-3-like protein 1 (CHI3L1), C-X-C motif chemokine ligand 1 (CXCL1), matrix metallopeptidase 9 (MMP9), and granzyme B (GZMB), and confirmed them in clinical PBMC samples. Furthermore, the disease-gene-drug interaction network revealed the potential of key genes as reference markers in T1DM.
Conclusion These results provide new insight into T1DM pathogenesis and novel biomarkers that could be widely representative reference indicators or potential therapeutic targets for clinical applications.
Citations
Citations to this article as recorded by
Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer Zhihao Zhao, Qilin Wang, Fang Zhao, Junnan Ma, Xue Sui, Hyok Chol Choe, Peng Chen, Xue Gao, Lin Zhang BMC Genomics.2024;[Epub] CrossRef
Bioinformatics analysis identifies TGF-β signaling pathway-associated molecular subtypes and gene signature in diabetic foot Guanggang Du, Jie Chen, Xuezhu Zhu, Zongdong Zhu iScience.2024; 27(3): 109094. CrossRef
Identification of Comorbidities, Genomic Associations, and Molecular Mechanisms for COVID-19 Using Bioinformatics Approaches Shudeb Babu Sen Omit, Salma Akhter, Humayan Kabir Rana, A. R. M. Mahamudul Hasan Rana, Nitun Kumar Podder, Mahmudul Islam Rakib, Ashadun Nobi, Ali Imran BioMed Research International.2023; 2023: 1. CrossRef
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus Mingshu Huang, Weixing Chen, Min Wang, Yisheng Huang, Hongyu Liu, Yue Ming, Yuanxin Chen, Zhengming Tang, Bo Jia BioDrugs.2023; 37(3): 331. CrossRef
Identification of the key genes of tuberculosis and construction of a diagnostic model via weighted gene co-expression network analysis Baiying Li, Lifang Sun, Yaping Sun, Libo Zhen, Qi Qi, Ting Mo, Huijie Wang, Meihua Qiu, Qingshan Cai Journal of Infection and Chemotherapy.2023; 29(11): 1046. CrossRef
Probing biological network in concurrent carcinomas and Type-2 diabetes for potential biomarker screening: An advanced computational paradigm Abdullah Al Marzan, Shatila Shahi, Md Sakil Arman, Md Zafrul Hasan, Ajit Ghosh Advances in Biomarker Sciences and Technology.2023; 5: 89. CrossRef
Transcriptional analysis of human peripheral blood mononuclear cells stimulated by Mycobacterium tuberculosis antigen Jing Wei, Fangzheng Guo, Yamin Song, Kun Xu, Feiyang Lin, Kangsheng Li, Baiqing Li, Zhongqing Qian, Xiaojing Wang, Hongtao Wang, Tao Xu Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Combining bioinformatics and machine learning algorithms to identify and analyze shared biomarkers and pathways in COVID-19 convalescence and diabetes mellitus Jinru Shen, Yaolou Wang, Xijin Deng, Si Ri Gu Leng Sana Frontiers in Endocrinology.2023;[Epub] CrossRef
Transcriptome analysis of peripheral blood mononuclear cells in patients with type 1 diabetes mellitus Zhaoxiang Wang, Li Zhang, Fengyan Tang, Zhongming Yang, Mengzhu Wang, Jue Jia, Dong Wang, Ling Yang, Shao Zhong, Guoyue Yuan Endocrine.2022; 78(2): 270. CrossRef
Background Prevailing insulin regimens for glycemic control in hospitalized patients have changed over time. We aimed to determine whether the current basal-bolus insulin (BBI) regimen is superior to the previous insulin regimen, mainly comprising split-mixed insulin therapy.
Methods This was a single tertiary center, retrospective observational study that included non-critically ill patients with type 2 diabetes mellitus who were treated with split-mixed insulin regimens from 2004 to 2007 (period 1) and with BBI from 2008 to 2018 (period 2). Patients from each period were analyzed after propensity score matching. The mean difference in glucose levels and the achievement of fasting and preprandial glycemic targets by day 6 of admission were assessed. The total daily insulin dose, incidence of hypoglycemia, and length of hospital stay were also evaluated.
Results Among 244 patients from each period, both fasting glucose (estimated mean±standard error, 147.4±3.1 mg/dL vs. 129.4±3.2 mg/dL, P<0.001, day 6) and preprandial glucose (177.7±2.8 mg/dL vs. 152.8±2.8 mg/dL, P<0.001, day 6) were lower in period 2 than in period 1. By day 6 of hospital admission, 42.6% and 67.2% of patients achieved a preprandial glycemic target of <140 mg/dL in periods 1 and 2, respectively (relative risk, 2.00; 95% confidence interval, 1.54 to 2.59), without an increased incidence of hypoglycemia. Length of stay was shorter in period 2 (10.23±0.26 days vs. 8.70±0.26 days, P<0.001).
Conclusion BBI improved glycemic control in a more efficacious manner than a split-mixed insulin regimen without increasing the risk of hypoglycemia in a hospital setting.
Background Metabolic syndrome (MetS) is reportedly a crucial risk factor for coronavirus disease 2019 (COVID-19). Since the epidemiological studies that examine this association are few and include small samples, we investigated the relationship between MetS and COVID-19 severity and death using a larger sample in the Republic of Korea.
Methods We analyzed 66,321 patients, 4,066 of whom had COVID-19. We used chi-square tests to examine patients’ characteristics. We performed logistic regression analysis to analyze differences in COVID-19 infection and clinical outcomes according to the presence of MetS.
Results Although MetS was not significantly associated with COVID-19 risk, acquiring MetS was significantly associated with the risk of severe COVID-19 outcomes (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.34 to 2.91; P=0.001). The mortality risk was significantly higher in COVID-19 patients with MetS (OR, 1.74; 95% CI, 1.17 to 2.59; P=0.006). Patients with abnormal waist circumference were approximately 2.07 times more likely to develop severe COVID-19 (P<0.001), and high-density lipoprotein cholesterol (HDL-C) levels were significantly associated with COVID-19; the mortality risk due to COVID-19 was 1.74 times higher in men with an HDL-C level of <40 mg/dL and in women with an HDL-C level of <50 mg/dL (P=0.012).
Conclusion COVID-19 is likely associated with severity and death in patients with MetS or in patients with MetS risk factors. Therefore, patients with MetS or those with abnormal waist circumference and HDL-C levels need to be treated with caution.
Citations
Citations to this article as recorded by
Heterogeneity in familial clustering of metabolic syndrome components in the multiethnic GENNID study Jia Y. Wan, Deborah Goodman, Sukh Makhnoon, Trina M. Norden‐Krichmar, Baolin Wu, Karen L. Edwards Obesity.2024; 32(1): 176. CrossRef
Associated Factors with Changes of Metabolic Abnormalities among General Population in COVID-19 Pandemic Eunjoo Kwon, Eun-Hee Nah, Suyoung Kim, Seon Cho, Hyeran Park Korean Journal of Health Promotion.2023; 23(2): 55. CrossRef
Association between metabolic syndrome and mortality in patients with COVID-19: A nationwide cohort study Hyo Jin Park, Jin-Hyung Jung, Kyungdo Han, Jean Shin, Yoojeong Lee, Yujin Chang, Kyeyeung Park, Yoon Jeong Cho, Youn Seon Choi, Seon Mee Kim, Ga Eun Nam Obesity Research & Clinical Practice.2022; 16(6): 484. CrossRef